Big data and benchmarking initiatives to bridge the gap from AlphaFold to drug design
Nat Chem Biol
.
2024 Aug;20(8):937-940.
doi: 10.1038/s41589-024-01570-z.
Authors
Matthieu Schapira
1
2
,
Levon Halabelian
1
2
,
Cheryl H Arrowsmith
1
3
4
,
Rachel J Harding
5
6
Affiliations
1
Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
2
Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
3
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
4
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
5
Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada. rachel.harding@utoronto.ca.
6
Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada. rachel.harding@utoronto.ca.
PMID:
38459278
DOI:
10.1038/s41589-024-01570-z
No abstract available
MeSH terms
Benchmarking*
Big Data*
Drug Design*
Humans
Proteins / chemistry
Substances
Proteins